Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DaxorDXR +3.73%47 3-Year EPS without NRI Growth Rate is 23.50% as of Jun. 2026, which is 1206% above its 10-year median of 1.80. GuruFocus rates DXR with a GF Score™ of 47/100 and a GF Value™ of $28.63 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 661 Medical Devices & Instruments companies, Daxor ranks better than 69.59% on this metric.
During the past 12 months, Daxor's average EPS without NRI Growth Rate was 956.30% per year.
During the past 3 years, the average EPS without NRI Growth Rate was 23.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Daxor was 128.50% per year. The lowest was -166.80% per year. And the median was 1.80% per year.
Daxor (NAS:DXR) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Daxor 3-Year EPS without NRI Growth Rate Related Terms
DXR vs NEPH, POCI, MLSS: 3-Year EPS without NRI Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, Daxor's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Daxor 3-Year EPS without NRI Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Daxor's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Daxor's 3-Year EPS without NRI Growth Rate falls into.
Daxor 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 23.50% mean?
Daxor (DXR) has a 3-Year EPS without NRI Growth Rate of 23.50% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Daxor and its competitors. This is 1206% above median its historical median of 1.80. According to the industry distribution chart, Daxor ranks #201 out of 661 companies in the Medical Devices & Instruments industry, placing it in the top 30.4%.
Is Daxor's 3-Year EPS without NRI Growth Rate too high?
Daxor's current 3-Year EPS without NRI Growth Rate of 23.50% is 1206% above median its 10-year median of 1.80. The Medical Devices & Instruments industry median 3-Year EPS without NRI Growth Rate is 8.10. Daxor's value of 23.50% is 190.1% above this industry median. Based on the distribution chart, Daxor ranks #201 out of 661 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Daxor has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Daxor's 3-Year EPS without NRI Growth Rate compare to NEPH and POCI?
According to the Medical Devices & Instruments industry distribution chart, Daxor ranks #201 out of 661 companies for 3-Year EPS without NRI Growth Rate. This puts Daxor in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 8.10. Daxor's value of 23.50% is 190.1% above this benchmark. While the company's 10-year median is 1.80 vs. the industry median of 8.10, Daxor has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EPS without NRI Growth Rate among Medical Devices & Instruments companies is 8.10, based on 661 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Daxor's current 3-Year EPS without NRI Growth Rate of 23.50% is 190.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Daxor and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EPS without NRI Growth Rate is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Daxor's current 3-Year EPS without NRI Growth Rate is 23.50%, which is 1206% above median its own 10-year median of 1.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daxor stock overvalued right now?
Based on GuruFocus' analysis, Daxor (DXR) is currently considered Possible Value Trap. The stock's GF Value™ is $28.63, compared to a current price of $10.85 — trading 62.1% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 23.50%, which is 1206% above median its 10-year median of 1.80 and 190.1% above the Medical Devices & Instruments industry median of 8.10. Daxor's overall GF Score™ is 47/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Daxor (DXR), the current 3-Year EPS without NRI Growth Rate is 23.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Daxor (DXR) Overvalued in 2026?
Based on GuruFocus' analysis, Daxor stock appears to be undervalued.
The current stock price of $10.85 is trading 62.1% below its estimated GF Value™ of $28.63.
GuruFocus considers Daxor to be Possible Value Trap.
Key valuation signals for DXR:
3-Year EPS without NRI Growth Rate: 23.50% (1206% above median its 10-year median of 1.80)
GF Value™: $28.63 vs. price of $10.85 (62.1% below fair value)
Industry Position: 190.1% above the Medical Devices & Instruments median (#201 of 661)
No single metric tells the full story. See the DXR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system.
47GF Score
Get the complete analysis for DXR
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DXR has been successfully added to your 
